Acquired lymphedema: An urgent need for adequate animal models

Cancer Research

Volumn 68, Issue 2, 2008, Pages 343-345

  Hadamitzky, Catarina ^a   Pabst, Reinhard ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN C;

CANCER SURGERY; DOG; GENE THERAPY; LAGOMORPH; LYMPH NODE DISSECTION; LYMPHANGIOGENESIS; LYMPHATIC DRAINAGE; LYMPHATIC SYSTEM; LYMPHEDEMA; NONHUMAN; POSTOPERATIVE EDEMA; PRIORITY JOURNAL; RABBIT; REVIEW; ANIMAL; DISEASE MODEL; EVALUATION; HUMAN; PATHOLOGY; RODENT;

ANIMALS; DISEASE MODELS, ANIMAL; DOGS; HUMANS; LAGOMORPHA; LYMPHEDEMA; RODENTIA;

EID: 39049123837     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-07-2454     Document Type: Review

References (20)

1. Szuba A, Rockson SG. Lymphedema: classification, diagnosis and therapy. Vasc Med 1998;3:145-56.
2. Williams AF, Franks PJ, Moffatt CJ. Lymphoedema: estimating the size of the problem. Palliat Med 2005;19:300-13.
3. Thompson M, Korourian S, Henry-Tillman R, et al. Axillary Reverse Mapping (ARM): a new concept to identify and enhance lymphatic preservation. Ann Surg Oncol 2007;14:1890-5.
4. Larson D, Weinstein M, Goldberg I, et al. Edema of the arm as a function of the extent of axillary surgery in patients with stage I-II carcinoma of the breast treated with primary radiotherapy. Int J Radiat Oncol Biol Phys 1986;12:1575-82.
5. Kanter MA, Slavin SA, Kaplan W. An experimental model for chronic lymphedema. Plast Reconstr Surg 1990;85:573-80.
6. Shin WS, Szuba A, Rockson SG. Animal models for the study of lymphatic insufficiency. Lymphat Res Biol 2003;1:159-69.
7. Knight KR, Collopy PA, McCann JJ, et al. Protein metabolism and fibrosis in experimental canine obstructive lymphedema. J Lab Clin Med 1987;110:558-66.
8. Cunningham DM, Olding M, Daniel RK. Microsurgical techniques in experimental lymphedema of the rabbit ear. Surg Gynecol Obstet 1978;147:877-80.
9. Szuba A, Skobe M, Karkkainen MJ, et al. Therapeutic lymphangiogenesis with human recombinant VEGF-C. FASEB J 2002;16:1985-7.
10. Rockson SG. Preclinical models of lymphatic disease: the potential for growth factor and gene therapy. Ann N Y Acad Sci 2002;979:64-75.
11. Fu K, Izquierdo R, Vandevender D, Warpeha RL, Fareed J. Transplantation of lymph node fragments in a rabbit ear lymphedema model: a new method for restoring the lymphatic pathway. Plast Reconstr Surg 1998;101:134-41.
12. Yoon YS, Murayama T, Gravereaux E, et al. VEGF-C gene therapy augments postnatal lymphangiogenesis and ameliorates secondary lymphedema. J Clin Invest 2003;111:717-25.
13. Cheung L, Han J, Beilhack A, et al. An experimental model for the study of lymphedema and its response to therapeutic lymphangiogenesis. BioDrugs 2006;20:363-70.
14. Rutkowski JM, Moya M, Johannes J, Goldman J, Swartz MA. Secondary lymphedema in the mouse tail: lymphatic hyperplasia, VEGF-C upregulation, and the protective role of MMP-9. Microvasc Res 2006;72:161-71.
15. Saito Y, Nakagami H, Morishita R, et al. Transfection of human hepatocyte growth factor gene ameliorates secondary lymphedema via promotion of lymphangiogenesis. Circulation 2006;114:1177-84.
16. Tabibiazar R, Cheung L, Han J, et al. Inflammatory manifestations of experimental lymphatic insufficiency. PLoS Med 2006;3:e254.
17. Becker C, Assouad J, Riquet M, Hidden G. Postmastectomy lymphedema: long-term results following microsurgical lymph node transplantation. Ann Surg 2006;243:313-5.
18. Wongtrungkapun R. Microsurgical lymphonodovenous implantation for chronic lymphedema. J Med Assoc Thai 2004;87:877-82.
19. Addiss DG, Brady MA. Morbidity management in the Global Programme to Eliminate Lymphatic Filariasis: a review of the scientific literature. Filaria J 2007;6:2-20.
20. Berens von Rautenfeld D, Schacht V. Fundamentals of comparative lymphology. In: Földi M, Földi E, Kubik S, editors. Textbook of lymphology. München: Urban and Fischer; 2003. p. 190-2.